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Abstract
The phosphoinositide 3-kinase (PI3K) pathway is activated in most advanced prostate cancers, yet so far treatments
with PI3K inhibitors have been at best tumorostatic in preclinical cancer models and do not show significant anti-
tumor efficacy in clinical trials. Results from tissue culture experiments in prostate cancer cells suggest that PI3K
inhibitors should be combined with other cytotoxic agents; however, the general toxicity of such combinations
prevents translating these experimental data into preclinical and clinical models. We investigated the emerging
concept of tumor-targeted synthetic lethality in prostate cancer cells by using the pan-PI3K inhibitor ZSTK474 and
the immunotoxin J591PE, a protein chimera between the single-chain variable fragment of the monoclonal antibody
J591 against the prostate-specific membrane antigen (PSMA) and the truncated form of the Pseudomonas aeruginosa
exotoxin A (PE38QQR). The combination of ZSTK474 and J591PE increased apoptosis within 6 hours and cell death
(monitored at 24–48 hours) in the PSMA-expressing cells LNCaP, C4-2, and C4-2Luc but not in control cells that do not
express PSMA (PC3 and BT549 cells). Mechanistic analysis suggested that induction of apoptosis requires Bcl-2–
associated death promoter (BAD) dephosphorylation and decreased expression of myeloid leukemia cell differentia-
tion protein 1 (MCL-1). A single injection of ZSTK474 and J591PE into engrafted prostate cancer C4-2Luc cells led to
consistent and stable reduction of luminescence within 6 days. These results suggest that the combination of a PI3K
inhibitor and a PSMA-targeted protein synthesis inhibitor toxin represents a promising novel strategy for advanced
prostate cancer therapy that should be further investigated.
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Introduction
Prostate cancer is the most common cancer diagnosed in men, repre-
senting the 14% of deaths from cancer and 25% of new cases of cancer
in the Western world. Although it is usually not fatal, the prognosis
for patients with advanced prostate cancer that spreads outside of the
prostate gland is poor, because of resistance to available treatments [1–3].
Most advanced prostate cancers have an overactive phosphoinositide
3-kinase/protein kinase B (PI3K/AKT) pathway. This pathway con-
trols cell growth, survival, motility, and angiogenesis, and it is asso-
ciated with higher Gleason grade, advanced stage, and unfavorable
prognosis [4–8].
The PI3K pathway is initiated by a receptor tyrosine kinase that
recruits and activates PI3K, resulting in an accumulation of phospha-
tidylinositol 3,4,5-trisphosphate in the plasma membrane. This
lipid second messenger recruits the AKT and the phosphoinositide-
dependent protein kinase 1 to the cell membrane, where AKT is
phosphorylated by phosphoinositide-dependent protein kinase 1 at
threonine 308. The mammalian target of rapamycin forms the mam-
malian target of rapamycin complex 2, which completes the activa-
tion of AKT by phosphorylation at serine 473. Fully activated AKT
translocates to the cytoplasm and nucleus, where it phosphorylates
downstream substrates [9].
Constitutive activation of the PI3K/AKT pathway in prostate cancer
is often led by functional loss of the tumor suppressor phosphatase
and tensin homolog deleted on chromosome 10 (PTEN) that de-
phosphorylates PI3K substrates or by activating mutations in the
PI3K itself [4,10,11]. For these reasons, PI3K inhibitors have been
considered an adjuvant therapy for advanced prostate cancer, and
pharmaceutical companies as well as academic laboratories are actively
developing small molecule inhibitors to specifically target the PI3K
[7,12–14]. At present, a number of PI3K inhibitors are in phase I
clinical trials (i.e., BEZ235, BKM120, and BGT226 from Novartis
[New York, NY], XL765 and XL147 from Exelixis [San Francisco, CA],
GDC0941 from Piramed/Genentech [San Francisco, CA], GSK1059615
from GlaxoSmithKline [Philadelphia, PA], SF1126 from Semafore
[Indianapolis, IN], andZSTK474 fromZenyakuKogyo [Tokyo, Japan];
source: www.clinicaltrials.gov), because they showed anti-proliferative
activity in preclinical models of solid tumors. However, phase II clinical
trials have shown only modest anti-tumor efficacy of PI3K inhibitors,
suggesting that malignant cells acquire resistance to monotherapy with
PI3K inhibitors. Thus, targeting only the PI3K pathway by inhibiting
one or more protein kinases on this pathway might not treat established
solid tumors [15]. Indeed, increasing number of reports show that com-
binations of PI3K inhibitors with other therapeutics may be needed for
stronger anti-tumor effects [16–19]. Yet such combinations use agents
with limited or no specificity in targeting cancer cells, which leads to
increased systemic toxicity, emphasizing the need for therapeutics that
selectively target prostate tumors.
The prostate-specific membrane antigen (PSMA) is a type II trans-
membrane protein with folate hydrolase and neurocarboxypeptidase
activities, with a short intracellular domain (amino acids 1–18), a trans-
membrane domain (amino acids 19–43), and a large extracellular
domain (amino acids 44–750) [20]. PSMA is expressed in normal pros-
tate epithelial cells at low levels, whereas expression increased by several
fold in tumors, especially in high-grade, metastatic, and androgen-
insensitive prostate carcinomas. PSMA is also expressed in the vascular
endothelium in a variety of tumors but not in normal tissues, which
further broadens its potential utility as a therapeutic target [21]. With
its abundant and restricted expression in tumors, its membrane loca-
tion, and rapid internalization, PSMA represents an attractive target
for prostate-selective cancer imaging and therapy. Antibodies to
PSMA have been shown to selectively deliver bacterial toxins or radio-
nuclides to prostate cancer cells in xenograft models of prostate cancer
and in clinical setting [22–29].
In this report, we treated prostate cancer cells with the PI3K inhibi-
tor ZSTK474 combined with the prostate-targeted immunotoxin
J591PE, based on a protein chimera of the single-chain variable frag-
ment of the J591 monoclonal antibody (J591scFv) and the truncated
form of the Pseudomonas aeruginosa exotoxin A (PE38QQR) [30]. The
combination triggered apoptosis in prostate cancer cells in tissue culture
within 6 hours, by inhibiting Bcl-2-associated death promoter (BAD)
dephosphorylation and decreasing expression of myeloid leukemia cell
differentiation protein 1 (MCL-1). In C4-2Luc cells, a human xeno-
graft model of advanced prostate cancer, the combination of ZSTK474
and J591PE showed a strong and stable reduction of tumor lumines-
cence, compared to transient effects of single-agent administration.
These results demonstrate for the first time that the combination of
ZSTK474 and J591PE represents an effective therapeutic approach
for advanced prostate cancer that should be further investigated.
Materials and Methods
Preparation of J591scFv and J591scFvPE38QQR (J591PE)
The J591scFv sequence was amplified from the SFG-pz1 [31]
using the primers 5′-TTATCTAGAATGTCTCATCACCATCAC-
CATCACGAGGTGCAGCTG-3′ (forward, 6× His, XbaI) and
5′-TACCCAAAGCTTTCATCATTTCAGGTCCAGCATGGT-3′
(reverse, HindIII) and cloned into pSF392 expression vector, a pBR322
derivative under the control of the Tac promoter (made in house,
unpublished), to generate pSF-J591scFv.
The J591scFv sequence was also amplified from the same template
using the primers 5′-TATTATACATATGGAGGTGCAGCTG-3′
(forward, NdeI) and 5′-TGATAAAAGCTTTTTTCAGGTCCAG-
CA-3′ (reverse, HindIII) and cloned into the pWD-PE38QQR
expression vector [32] under the control of the T7 bacteriophage late
promoter to generate a pWD-J591scFv-PE38QQR vector. Each clone
was sequenced (Wake Forest University Core Facility) and amplified
in Escherichia coli DH5α cells.
J591ScFv was expressed in E coli XL1 Blue cells and extracted from
the bacterial periplasm as previously reported [33]. Subsequently, we
added a purification step consisting of a HisTrap HP column followed
by a gel filtration on Superdex 75 100/300 GL size exclusion column
(GE Healthcare Life Sciences, Uppsala, Sweden).
The recombinant protein J591scFvPE38QQR (J591PE) was
expressed in E coli BL21 as previously described [34]. Briefly, trans-
formed bacteria were grown in Luria-Bertani (LB) medium supple-
mented with 100 μg/ml ampicillin on an orbital shaker O/N at 37°C
and at A600 = 0.7. Recombinant protein expression was induced by
addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for
90 minutes. J591PE was extracted from inclusion bodies by using
7 M guanidine (MP Biomedicals, Salon, OH) and 1,4-dithiothreitol
(Sigma, St Louis,MO). Protein refolding was performed in a 0.1MTris
buffer containing arginine/L-glutathione oxidase (Sigma-Aldrich,
St Louis, MO). The recombinant immunotoxin was further dialyzed
and purified by using a Q Sepharose ion exchange liquid chromatog-
raphy system (GE Healthcare Life Sciences). Purification of J591scFv
and J591PE was evaluated using Coomassie staining (PhastGel Blue R;
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GE Healthcare Bio-Sciences, Uppsala, Sweden) after sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels ac-
cording to the manufacturer’s protocol. The most purified preparations
were also filtered using a 0.22-μm syringe filter, evaluated for activity,
aliquoted, and stored in phosphate-buffered saline (PBS) at −20°C for
subsequent experiments.
Cell Cultures
The hormone-responsive prostate cancer LNCaP and breast cancer
BT-549 cell lines were purchased from ATCC (Manassas, VA). The
androgen-independent prostate cancer LNCaP subline C4-2 and the
mouse prostate epithelial WF3 cells were generous gifts fromDr Leland
Chung (Cedars-Sinai Medical Center, Los Angeles, CA) and Dr Scott
Cramer (University of Colorado Denver, Aurora, CO), respectively.
C4-2Luc cells were generated as reported previously [35].
All cells were maintained in a humidified atmosphere (5% CO2) at
37°C, using RPMI 1640 (C4-2, C4-2Luc and BT549) and T-Medium
(LNCaP), supplemented with 10% FBS (5% for LNCaP). BT549
medium was also supplemented with 0.023 U/ml insulin. WF3 cells
were cultured in PTEN medium [Dulbecco’s modified Eagle’s
medium/F12 supplemented with 1% FBS, 1% BSA, 10 ng/ml cholera
toxin, 28 μg/ml BPE, 8 μg/ml insulin, 2.3 μM α-tocopherol, 5 μg/ml
transferrin, 1 nM MnCl2, 500 nM Na2SiO3, 1 nM (NH4)6Mo7O24,
5 nM NH4VO3-(Na3VO4), 500 pM NiCl2, 5 pM SnCl2, 20 nM
H2SeO3, and 10 ng/ml epidermal growth factor]. All tissue culture
reagents were purchased from Invitrogen (Carlsbad, CA).
If not otherwise indicated, cells were seeded as follows: in 96-well
plates for the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS)/phenazine methosulfate
(PMS) assay (2 × 103/well) and for 3-(4, 5 dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT; 5 × 103/well); in 6-well plates
for time-lapse video microscopy (1 × 105/well for C4-2, C4-2Luc,
PC3, and BT549 and 1.5 × 105/well for LNCaP cells) and 4 × 105 in
6-cm Petri dishes for Western blot analysis and caspase 3 assays. Cells
were kept in culture for 24 to 48 hours to reach about 80% confluence
before starting any experiments. During experiments, cells were kept
in a serum-free medium condition as described previously [36] (except
LNCaP cells, which were kept in a medium supplemented with
2.5% FBS).
MTS/PMS and MTT Cell Viability Assays
For MTS/PMS assay, J591PE was administered to C4-2 and PC3
cells at a range of 0.1 to 1000 ng/ml, with or without 1 hour of pre-
incubation with J591scFv (50:1). Cells were incubated for 48 hours,
and cell viability was measured using the MTS/PMS dye (Promega,
Madison, WI) in triplicate, following the manufacturer’s instructions.
For MTT assay, cells were incubated with drugs for 48 hours and
cell viability was measured using MTT dye (Sigma-Aldrich) in triplicate,
according to the manufacturer’s instructions.
Plates were analyzed using a SpectraMax Plus384 plate reader
(Molecular Devices, Santa Clara, CA).
Caspase 3 Assay
Apoptosis in whole-cell populations was assessed by monitoring
caspase 3 activity with the specific fluorogenic substrate Ac-DEVD-
7-amido-4-trifluoromethylcoumarin (Bachem, Torrance, CA), as pre-
viously reported [12]. Adherent and floating cells were collected and
lysed using a cold lysis buffer (1% NP-40, 150 mM NaCl, 20 mM
Hepes, 1 mM EDTA, 1 mM DTT, and 5 μg/ml aprotinin, leupeptin,
and pepstatin, respectively). Fluorescence was recorded 15 minutes
each for 1 hour using a VersaFluor fluorometer (Bio-Rad Laboratories,
Hercules, CA). Caspase 3 activity was expressed in arbitrary units and
calculated using Excel 2010 (Microsoft Corporation, Redmond, WA).
Western Blot Analysis
Media were removed, and cells were washed gently twice using
cold PBS on ice. Lysates were generated using cold 20 mM Hepes,
150 mM NaCl, 1 mM EDTA, 0.5% Na+ deoxycholate, 1% NP-40,
and 1 mM DTT (pH 7.4) buffer containing protease inhibitors
(10 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml pepstatin, 1 mM
benzamidine, and 1 mM PMSF) and phosphatase inhibitors (1 mM
NaVO4, 50 mM β-glycerophosphate, 40 mM p-nitrophenylphosphate,
40 mM NaF, and 1 μg/ml microcystin). All reagents were purchased
from Sigma-Aldrich. Cell lysates were clarified by centrifugation
at 15,000 rpm for 15 minutes at 4°C, and then the supernatant was
collected and protein content was measured by a Bradford assay
(Bio-Rad Laboratories) according to the manufacturer’s directions.
Proteins were separated on SDS-PAGE on 12% gels and transferred
onto a 0.45-μm nitrocellulose membrane (PerkinElmer, Waltham,
MA). Western blot analysis was performed with the Odyssey CLx
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE), according
to the manufacturer’s instructions.
Rabbit polyclonal anti–p-AKT (T308), anti-AKT, anti–p-BAD
(S112), anti-BAD, and anti–cleaved poly(ADP-ribose) polymerase
(PARP; Asp214), anti–cleaved caspase 3 (Asp175), and mouse mono-
clonal anti–caspase 3, anti–caspase 7, anti–p-AKT (S473), and anti-
tubulin were purchased from Cell Signaling Technology (Beverly,
MA); rabbit anti–MCL-1 and anti–β-actin were purchased from
Stressgen Biotechnologies Inc (Philadelphia, PA) and Sigma-Aldrich,
respectively. Mouse monoclonal J591 antibody was purchased from
DrN. Bander (Weill Medical College of Cornell University, New York,
NY) and used to detect PSMA in prostate cancer cells. Secondary goat
anti-mouse IRDye 680 and goat anti-rabbit IRDye 800 were both
purchased from LI-COR Biosciences. Protein bands were quantified
using ImageJ software (National Institutes of Health, Bethesda, MD).
Metabolic Labeling
Cells were grown in cysteine/methionine-free Dulbecco’s modified
Eagle’s medium with 5% FBS for 5 hours in the presence of either
100 μg/ml cycloheximide, 1 μg/ml J591PE, or 1 μg/ml J591PE and
10 μg/ml J591 antibody followed by addition of 10 μCi/ml S35Cys/
Met Easy Tag Express labeling mix (PerkinElmer) for 1 hour in tripli-
cate for each data point. Cells were then washed with PBS and protein
lysates were collected as described in the Western Blot Analysis section.
Protein lysates (5 μl) were spotted on a nitrocellulose membrane,
washed, dried, and placed into scintillation vials with 2 ml of scintilla-
tion liquid. Radioactivity was quantified using an LS 6500 Multi-
Purpose Scintillation Counter (Beckman Coulter, Fullerton, CA). In
addition, 25 μg of protein lysates was separated on 10% SDS-PAGE,
transferred into a nitrocellulose membrane, and imaged using a
Typhoon Trio (GE Healthcare Bio-Sciences, Piscataway, NJ).
MCL-1–Targeted shRNA
An MCL-1–targeted shRNA was generated using the lentiviral
vector–based RNAi technology previously described [37]. To find a
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target sequence, we chose a 23-nucleotide MCL-1 sequence found in
MCL-1 isoform 1 that has no homology in the mice and has a high
guanine/cytosine (GC) percentage to increase efficiency. Our target
sequence (5′-AAT TCA AAA AAT TGT TTA ACT CGC CAG
TCC CGT A-3′) targets a region between the transmembrane domain
and the carboxyl terminus of human MCL-1. Briefly, polymerase chain
reaction (PCR) was used to amplify the U6 promoter region that was di-
gested with BamHI and HindIII restriction sites. Oligonucleotides con-
taining the MCL-1 target sequence, a six-nucleotide hairpin sequence,
were annealed and digested byHindIII-EcoRI. The pLL3.7 lentiviral vec-
tor was digested with BamHI and EcoRI. The U6 promoter and MCL-1
target oligonucleotide were ligated atHindIII, and the remaining digested
ends were ligated to the digested pLL3.7 vector at BamHI and EcoRI
sites. A scrambled RNA oligonucleotide sequence 5′-GGTACGGT-
CAGGCAGCTTCT-3′ was used as a control.
Inducible FLAG–MCL-1
Complementary oligonucleotides encoding FLAG epitope and several
restriction sites were synthesized by GenScript (Piscataway, NJ) and
cloned into the EcoRI and HindIII sites of pUC57 (termed pUC57-
FLAG + ReS). The open reading frame of MCL-1 was PCR amplified
from green fluorescent protein (GFP)–MCL-1 with primers containing
5′ BamHI and 3′ XbaI sites and cloned into PCR-BluntII-TOPO vector
(Zero Blunt TOPO PCR cloning kit; Invitrogen, Grand Island, NY).
Sequence-verified PCR-amplified clones were used to isolate FLAG–
MCL-1 fragment (digested with EcoRI and XbaI) and cloned into
tetracycline-inducible lentiviral vector, pTET-ON2. Doxycycline induc-
tion experiments were performed with TET-FBS–containing medium
with 1 mg/ml doxycycline for 24 hours.
Transfections were performed at 60% to 70% confluence using Lipo-
fectamine (Invitrogen) according to the manufacturer’s recommendations.
Time-Lapse Video Microscopy
Time-lapse video recording was performed on an Axiovert 100 micro-
scope (Carl Zeiss Microscopy, Thornwood, NY) equipped with a
moving stage and climate control chamber (37°C, 5% CO2) and con-
trolled by OpenLab software (Improvision Inc, Lexington, MA). In
experiments with cells transiently transfected with FLAG–MCL-1 or
shRNA expression vectors that also express GFP, fluorescent images of
GFP-positive cells were recorded and analyzed for apoptosis morphol-
ogy. In an experiment where total population of cells was analyzed,
bright fields were recorded. Four randomly chosen fields containing
around 100 to 150 cells for each treatment were recorded. Data are
expressed as percentage of apoptotic-like morphology cells versus living
cells for each hour of treatment.
Prostate Cancer Xenograft Model
Six-week-old BALB/c nude mice (Charles River Laboratories,
Wilmington, MA) received three subcutaneous injections of 2 ×
106 cells (C4-2Luc) with Matrigel (Sigma-Aldrich). Three injections
were performed to increase the probability of generating xenografts,
using an insulin syringe with a 29-gauge needle. When tumors reached
a diameter of 0.5 cm, intratumoral injections of ZSTK474 (375 μg/kg
in 30 μl of DMSO), J591PE (2.5 mg/kg in 30 μl of PBS), or the com-
bination were conducted under anesthesia as reported in the animal
protocol. Tumors were also injected with vehicle controls (30 μl of
DMSO or 30 μl of PBS) or J591scFv (2.5 mg/kg in 30 μl of PBS).
The experimental protocol was approved by the Wake Forest University
Institutional Animal Care and Use Committee.
In Vivo Non-Invasive Imaging
Tumor growth was analyzed using a Xenogen IVIS 100 optical im-
aging system (Caliper Life Sciences, Hopkinton, MA) while animals
were anesthetized with 2% isoflurane/O2. To account for background
and nonspecific luminescence, mice were imaged before the injection
of 100 μl of luciferase substrate (consisting of 3.5 mg/ml luciferin in
PBS) and imaged 15 minutes later for 1 minute in the position of
interest. Whole-body images were obtained using Living Image soft-
ware provided with the imaging system. A grayscale photographic
image and the bioluminescent color image were superimposed to
provide an anatomic registration of the light signal. The region of
interest (ROI) was manually selected over the luminescent signal,
and the intensity was recorded as photons per second within an ROI.
Statistical Analysis
Probability (P) values were calculated using the one-way analysis of
variance test; P values ≤ .05 were considered statistically significant.
The results are expressed as means ± SEM.
Results
J951PE Toxin Selectively Inhibits Growth of Cells that
Express PSMA
J591 monoclonal antibodies against PSMA have been extensively
characterized for selectivity toward prostate cells that express PSMA
and used for clinical imaging of prostate tumors and targeted toxin
delivery in preclinical models [38–40]. Importantly for therapeutic
applications and especially for toxin delivery, these antibodies are
rapidly internalized on binding to prostate cancer cells [41]. To selec-
tively inhibit protein synthesis in prostate cancer cells, we generated
a chimera of single-chain variable fragment of J591 monoclonal anti-
body against PSMA and the translocation and catalytic domains of a
P aeruginosa exotoxin A (PE38QQR) that ribosylates and inactivates
elongation factor 2 (Figures 1A and W1A) [30,42]. PE38QQR is a
truncated mutant form of P aeruginosa exotoxin A that lacks cell bind-
ing domain 1a and 16 amino acids from cell binding domain 1b, in
which lysines 590 and 606 are replaced with glutamines and lysine
613 with arginine. PE38QQR has been used to produce extremely
potent immunotoxins that caused complete regression of human
carcinoma growth in mice [30,32,33].
Analysis of expression of PSMA and PTEN in LNCaP, C4-2,
C4-2Luc, PC3, WF3, and DU145 cells (prostate cancer) and in
BT549 (breast cancer) cells showed that LNCaP, C4-2, and C4-2Luc
cells express PSMA and do not express PTEN; PC3, WF3, and
BT549 cells do not express PSMA or PTEN; and DU145 cells express
PTEN but do not express PSMA (Figure 1B).
We examined the effects of J591PE on protein synthesis by
metabolic labeling of C4-2Luc, PC3, and DU145 cells with S35Cys
and S35Met. Incubation with J591PE for 6 hours selectively inhibited
S35 incorporation into PSMA-positive C4-2Luc cells but not into
PSMA-negative PC3 or DU145 cells (Figures 1C and W1B). In
contrast, cycloheximide inhibited protein synthesis in all cell lines.
Consistent with selective inhibition of protein synthesis, cell viabil-
ity assays showed that J591PE decreased the number of viable C4-2
(PSMA-positive) cells after 48 hours of incubation but had no effect
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on PSMA-negative PC3 cells (Figure 1D). Specificity of J591PE toxin
to PSMA epitope was confirmed by competition assay using the single-
chain antibody J591scFv not conjugated with toxin as a competitor in
metabolic labeling and cell viability assays. Ten-fold excess of
unconjugated J591 antibodies prevented inhibition of protein syn-
thesis and decreased long-term cytotoxic effects in C4-2Luc cells by
J591PE (Figures 1, C andD, W1B, and W2). Control treatments with
J591scFv did not reduce viability of C4-2 cells, whereas treatments
with cycloheximide decreased viability in all cell lines irrespective of
PSMA expression (Figure W2).
Combination of the PI3K Inhibitor ZSTK474 with J591PE
Induces Apoptosis in Prostate Cancer Cells
Treatment of C4-2 cells with increasing concentrations of PI3K
inhibitor ZSTK474 induced minimal apoptosis at 0.2 μg/ml that
peaked at 2 μg/ml as judged by measuring caspase 3 activity and
cleavage of caspase 3/7 substrate PARP (Figure 2A, left panel); at this
concentration, maximal inhibition of PI3K/AKT signaling was
achieved (Figure W3). At the same time, treatments with J591PE
at the range of 0.001 to 10 μg/ml did not induce detectable apoptosis
(Figure 2A, right panel). We used a range of concentrations to find
Figure 1. Characterization of J591PE chimera toxin. (A) Scheme of the J591scFvPE38QQR (J591PE) immunotoxin: a chimera between
the single-chain variable fragment of the J591 antibody (J591scFv) and the truncated form of P aeruginosa exotoxin A (PE38QQR) is
shown. (B) Analysis of PSMA and PTEN expression in a panel of prostate cancer cells (LNCaP, C4-2, C4-2Luc, PC3, WF3, and DU145)
and breast cancer cells (BT549). (C) J591PE selectively inhibits protein synthesis in PSMA-positive C4-2Luc cells. PSMA-negative
PC3, DU145, and PSMA-positive C4-2Luc cells were treated with cycloheximide (CX) or J591PE for 5 hours and labeled with S35cystein-
methionine for 1 hour. Where indicated, C4-2Luc cells were preincubated with 10 μg/ml J591 antibody for 1 hour before adding J591PE
chimera toxin. (D) Cytotoxic effects of J591PE on C4-2 and PC3 cells. J591PE was administered alone and in combination with J591scFv
(1 hour of preincubation; 50:1 for each J591PE concentration used) to C4-2 and PC3 cells. After 48 hours, an MTS/PMS assay was
performed, measuring cell viability. Data were plotted as percentage of control versus concentration of the toxin used. Results in C and
D are expressed as means ± SEM, n = 3.
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the best combination of ZSTK474 and J591PE for inducing apop-
tosis (the lowest doses with the strongest pro-apoptotic effects). The
combination of 2 μg/ml ZSTK474 and 1 μg/ml J591PE (combina-
tion C4; Figure 2B) increased caspase 3 activity by 7-fold compared
with a 2.5-fold increase in C4-2 cells treated with ZSTK474 and a
1.2-fold increase in cells treated with J591PE, as single agents. Time
course analysis showed that significant increase of caspase activity and
PARP cleavage was detected in C4-2 cells 6 hours after treatments
with combination C4 (2 μg/ml ZSTK474 and 1 μg/ml J591PE) with
further increase at later time points (Figure 2C ).
To further characterize pro-apoptotic effects of the combination
of ZSTK474 and J591PE, we followed cell death by time-lapse video
Figure 2. Optimization of apoptosis induction by the combination of ZSTK474 and J591PE in prostate cancer cells. (A) C4-2 cells treatedwith
either ZSTK474 (left panel) or J591PE (right panel) show modest or no increase of caspase 3 activity/PARP cleavage at 6 hours (green,
c-PARP; red, tubulin). (B) Dose-response analysis of caspase 3 activity and PARP cleavage in C4-2 cells treated with the combination of
ZSTK474 and J591PE. On the basis of these results, 2 μg/ml ZSTK474 and 1 μg/ml J591PE were used for subsequent experiments (referred
to as combination C4). (C) Time-course analysis of the caspase 3 activity (left panel) and PARP cleavage (right panel) in C4-2 cells treated
with the combination of ZSTK474 and J591PE. Results are expressed as means ± SEM, n = 2. Representative Western blots are shown.
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Figure 3. Combination of ZSTK474 and J591PE promotes apoptosis in C4-2Luc cells. (A) Combination of ZSTK474 and J591PE promotes
apoptosis at 6 hours in C4-2Luc cells, as suggested by analysis of caspase 3 activity, cleavage of effector caspases 3 and 7, and cleavage
of PARP as well as analysis of cell morphology by time-lapse video recording. (B) Combination of ZSTK474 and J591PE does not promote
apoptosis in PC3 cells, when compared to single-agent treatments. Results are expressed as means ± SEM, n = 2 (caspase 3 assay) and
n = 4 (time-lapse video microscopy). Representative Western blots and time-lapse video microscopy frames (original magnification, ×20)
are shown (vehicle, DMSO; combination, ZSTK474 + J591PE).
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microscopy, measured caspase activity, and examined cleavage of
effector caspase 3, caspase 7, and PARP in a panel of cell lines. Consis-
tent with the results in C4-2 cells, the combination of ZSTK474 and
J591PE increased apoptosis in PSMA-positive cell lines. Induction of
apoptosis in LNCaP, C4-2, and C4-2Luc cells treated with the com-
bination of ZSTK474 and J591PE was confirmed by time-lapse video
microscopy, detection of the loss of full-length caspase 3, and detection
of cleaved forms of caspase 7 and of cleaved PARP (Figures 3A and
W4A). In contrast, combined treatments with ZSTK474 and J591PE
failed to significantly increase apoptosis in PC3, WF3, and BT549 cell
lines that do not express PSMA (Figures 3B, W3, and W4B). However,
administration of the protein synthesis inhibitor cycloheximide with
ZSTK474 increased caspase 3 activity in PC3, DU145, WF3, and
BT549 cells, confirming that the combination of a protein synthesis in-
hibitor with a PI3K inhibitor can increase apoptosis in PSMA-negative
cells (FigureW5).MTT assay supported these data by showing decreased
viability of PSMA-positive C4-2 cells after 48 hours of incubation with
ZSTK474 and J591PE and further significant decrease of viability in
cells treated with the combination of J591PE and ZSTK474 (Fig-
ure W2A). In PSMA-negative cells, PC3 and DU145 treatments with
J591PE did not reduce viability nor augmented the toxic effects of
ZSTK474 in these cells (Figure W2, B and C).
Altogether these results confirm specificity of apoptosis induction by
the combination of ZSTK474 and J591PE in PSMA-expressing cells.
Inhibition of the PI3K/AKT/BAD Pathway and Loss of
MCL-1 Is Needed to Induce Apoptosis
BAD has been recognized as a sentinel of apoptosis and a target
responsible for pro-apoptotic effects of the PI3K/AKT inhibitors in
numerous cell lines, including prostate cancer cells [43,44]. Analysis
of AKT and BAD phosphorylation byWestern blot analysis confirmed
that in all PTEN-deficient cell lines, the PI3K/AKT pathway was con-
stitutively active and BAD was phosphorylated, whereas no phosphor-
ylation of AKT or BAD was detected in PTEN-positive DU145 cells
(Figures 4 and W5C ). Administration of ZSTK474 inhibited both
AKT and BAD phosphorylation. However, robust apoptosis was in-
duced only in C4-2, C4-2Luc, and LNCaP cells that express PSMA
(a target of J591PE), when cells were treated with the combination
of ZSTK474 and J591PE, whereas treatment with ZSTK474 alone
did not induce substantial apoptosis (Figures 3A and W4). These
results suggested that inhibition of the PI3K/AKT/BAD axis alone
is not sufficient to induce apoptosis that may promote cell death in
PTEN-deficient prostate cancer cells.
Recently, it was proposed that loss of induced MCL-1, an anti-
apoptotic Bcl-2 family protein characterized by a short half-life, pro-
vides a possible mechanism for the pro-apoptotic effect of protein
synthesis inhibitors [45–47]. To test whether loss of MCL-1 in human
prostate cancer cells may be responsible for apoptosis induction by the
combination of ZSTK474 and J591PE, we assessed MCL-1 protein
levels in these cell lines. Loss of MCL-1 expression was detected
in C4-2Luc cells treated with the C4 combination (1 μg/ml J591PE
and 2 μg/ml ZSTK474) and in cells treated with higher doses of both
agents (Figure 5A). In the comparison of MCL-1 levels in a panel of
cell lines treated with pro-apoptotic agents, C4-2Luc cells showed
strongest decrease of MCL-1 expression, followed by C4-2 and LNCaP
cells, whereas no apparent change in MCL-1 expression was detected
in PC3 and BT549 cells (Figure 5B). Thus, levels of MCL-1 expression
are inversely proportional to levels of apoptosis in these cell lines. To
test the role of MCL-1 in apoptosis induced by the combination of
ZSTK474 and J591PE, we compared apoptosis in cells in which
MCL-1 was knocked down with an shRNA and in cells that ectopically
expressed doxycycline-inducible FLAG–MCL-1. Analysis of apoptosis
in cells that express an MCL-1–specific shRNA or a scrambled shRNA
showed that loss of MCL-1 expression sensitized cells to ZSTK474
administration, resulting in increased apoptosis as determined by time-
lapse video microscopy (Figure 5C ). Conversely, ectopic expression
of FLAG–MCL-1 antagonized the effects of ZSTK474 and J591PE,
decreasing the levels of apoptosis when cells were treated with both
agents (Figure 5D).
Combination of the PI3K Inhibitor ZSTK474 and the
Immunotoxin J591PE Induces Regression of Human
Prostate Cancer Xenografts
To determine whether the combination of ZSTK474 and J591PE
inhibits tumor growth in vivo, experiments were conducted in C4-
2Luc xenografts that express firefly luciferase. Recently, we have shown
Figure 4. ZSTK474 alone or in combination with J591PE inhibits the PI3K/AKT pathway and BAD phosphorylation in PTEN-deficient cell
lines. Inhibition of the PI3K/AKT pathway by ZSTK474 was followed in LNCaP, C4-2, C4-2Luc, PC3, and BT549 cells by monitoring the
phosphorylation levels of AKT (T308 and S473) and BAD (S112). Representative Western blots are shown (vehicle, DMSO).
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that injection of PI3K inhibitor ZSTK474 into C4-2Luc xenografts
induced apoptosis and in parallel decreased tumors luminescence;
thus, growth of C4-2Luc xenografts could be monitored by non-
invasive optical imaging [48].
ZSTK474 injected in C4-2Luc tumors in combination with J591PE
reduced the luminescence levels for at least 5 days, whereas single
injections with either ZSTK474 or J591PE led to a transient reduction
of luminescence (Figure 6, A and C ). C4-2Luc tumors injected with
J591scFv (antibody without toxin) or PBS (solvent for J591PE) con-
tinue to grow (Figure W6, A and B), whereas injections of DMSO
(solvent for ZSTK474) stabilized luminescence for 5 days. Analysis of
C4-2Luc xenograft tissues forMCL-1 expression, BADphosphorylation,
p-AKT, and apoptosis markers (cleaved PARP and cleaved caspase 3;
Figure 6B) showed decreased MCL-1 expression in C4-2Luc tumors
treated with either agent, with further decrease in C4-2Luc xenografts
injected with ZSTK474 and J591PE. Consistent with a long-term
reduction of luminescence, more cleaved PARP and cleaved caspase 3
was observed in C4-2Luc xenografts treated with the combination of
J591PE and ZSTK474, supporting the hypothesis that simultaneous
loss of MCL-1 expression and BAD dephosphorylation is requested
to increase apoptosis in PSMA-expressing prostate tumors in vivo, as
previously observed in vitro.
Discussion
Castration-resistant prostate cancer is a late-stage and lethal form of
prostate cancer for which no curative treatments are available at present.
Despite several ongoing trials, there is an urgent need for new agents or
rational drug combinations to eliminate growth of androgen-insensitive
malignant cells [49,50]. Accumulating evidence supports the role of
Figure 5. Loss of MCL-1 contributes to apoptosis induction by the combination of ZSTK474 and J591PE. (A) Analysis of MCL-1 expression
in C4-2 cells treated with a range of combinations (C1–C6) of ZSTK474 and J591PE. Concentrations of each agent are shown in Figure 1B.
(B) Analysis of MCL-1 expression in a panel of PTEN-positive (LNCaP, C4-2, and C4-2Luc) and PTEN-negative (PC3 and BT549) cells treated
with ZSTK474, J591PE, or the combination of both for 6 hours. Representative Western blots are presented; numbers show fold change
of MCL-1 band intensity compared to cells treated with vehicle (DMSO). (C) Knockdown of MCL-1 with shRNA sensitizes C4-2Luc cells
treated with ZSTK474 to apoptosis. C4-2Luc cells were infected with either MCL-1–specific shRNA or scrambled shRNA expressed in a
lentiviral vector with GFP marker, and apoptosis morphology in GFP-positive cells was followed by time-lapse video microscopy. Data
for the 6-hour time point are shown. Insert showsWestern blot analysis of MCL-1 expression (green) in GFP-positive (left) and GFP-negative
(right) cells. β-Actin (red) was used as a loading control. (D) Expression of FLAG–MCL-1 protects C4-2Luc cells from apoptosis. C4-2Luc cells
were transfected with vectors encoding FLAG–MCL-1 under doxycycline-inducible promoter and GFP and were treated and analyzed as
in C. Insert shows doxycycline-inducible expression of FLAG–MCL-1. Results are expressed as means ± SEM, n = 3.
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anti-apoptotic signaling cascades through protein kinases in the thera-
peutic resistance of castration-resistant prostate cancer. In this disease,
the PI3K/AKT pathway is prominent as a result of gain-of-function
mutations in PI3Kα or loss of PTEN, which is associated with cancer
progression, high Gleason grade, and poor prognosis [11,51]. Thus,
PI3K inhibitors were considered a suitable form of therapy, but their
potential as anti-tumor agents has yet to be realized. Early clinical trials
suggest that these drugs are well tolerated in patients and at least
partially inhibit the PI3K pathway in tumors. However, clinical re-
sponse is poor, even in patients with PTEN loss or activating mutations
of the PI3K [52,53].
Consistent with the results of these clinical trials, our earlier experi-
ments in prostate cancer cells (and experimental results depicted in
Figure 2) show that PI3K inhibitors induce modest apoptosis in
PTEN-negative prostate cancer cells, but the combination of PI3K
inhibitors and protein synthesis inhibitors increases the levels of
apoptosis able to promote prostate cancer cell death (Yancey et al.,
in press) [43].
Although general protein synthesis inhibitors have been used in
the clinic, they have substantial side effects [54,55]. To reduce these
agents’ toxicity, we produced a novel prostate cancer–targeted immuno-
toxin (J591PE), by generating a recombinant protein chimera between
the single-chain variable fragment of the monoclonal antibody J591
(J591scFv) and the truncated form of the P aeruginosa exotoxin A
(PE38QQR). The result is a prostate-specific protein synthesis inhibi-
tor that targets PSMA-expressing cells. A combination of J591PE with
the pan-PI3K inhibitor ZSTK474 promotes apoptosis both in vitro
and in vivo in xenograft tumors, when compared with single-agent treat-
ments. A single injection of the combination of ZSTK474 and J591PE
is sufficient to induce apoptosis and prolonged inhibition of C4-2Luc
xenograft luminescence.
Anti-apoptotic signaling by a hyperactive PI3K pathway has been
suggested as the likely cause of therapeutic resistance of prostate cancer
cells [7]. Analysis of downstream effectors identified BAD as a major
target of the constitutively active PI3K pathway in prostate cancer cells
and a convergence node for several other anti-apoptotic signaling path-
ways [43,56]. Subsequent experiments, including the results presented
above, argue that BAD dephosphorylation is necessary but not suffi-
cient to induce apoptosis. However, when BAD dephosphorylation
is combined with decreased MCL-1 expression, prostate cancer cells
Figure 6. Combined administration of ZSTK474 and J591PE induces regression of C4-2Luc prostate cancer tumors in nude mice.
(A) Dynamics of luminescence of C4-2Luc tumors after a single local injection of DMSO, ZSTK474 (375 μg/kg), J591PE (2.5 mg/kg), or
the combination of ZSTK474 and J591PE. Luminescence was monitored for 6 days by optical imaging and expressed as fold change com-
pared to luminescence at day 0. Results are expressed as means ± SEM, n = 4 (DMSO) and n = 10 (ZSTK474, J591PE, combination).
(B) Western blot analysis of C4-2Luc tumors excised 6 hours after injections of drugs. Combination of ZSTK474 and J591PE decreases
MCL-1 protein levels and promotes apoptosis (increased c-caspase 3 and c-PARP) when compared to vehicle (DMSO). ZSTK474 alone
or in combination with J591PE inhibits the phosphorylation of p-AKT (S473) and p-BAD (S112). Representative Western blots are shown.
(C) Representative images of nude mice recorded on IVIS 100 luminescent imaging station showing ROI, 15 minutes after intraperitoneal
(i.p.) luciferin injection. Representative images of background luminescence outside the tumors are shown in Figure W6C .
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undergo apoptosis. BAD cannot bind MCL-1; therefore, MCL-1 ex-
pression prevents apoptosis in cells with dephosphorylated BAD [57].
Analysis of MCL-1 expression in cells that undergo apoptosis on treat-
ment with J591PE has shown that J591PE triggers loss of MCL-1
expression, whereas experiments with shRNA-mediated knockdown
and ectopic expression of FLAG–MCL-1 confirmed the determinant
role of MCL-1 in apoptosis induction in prostate cancer cells (Fig-
ure 4). Taken together, these experiments point at MCL-1 loss as the
primary mechanism behind the pro-apoptotic effects of the immuno-
toxin J591PE.
Increased MCL-1 expression has been associated with prostate can-
cer progression and may represent a mechanism of tumor resistance to
apoptosis-inducing therapies [58].
In summary, our results demonstrate synthetic lethality of a PI3K
inhibitor and a prostate-directed protein synthesis inhibitor immuno-
toxin, suggesting that BAD phosphorylation and MCL-1 expression
could be used as biomarkers to predict anti-tumor efficacy in prostate
cancer cells with a constitutive activated PI3K/AKT pathway. Future
experiments will determine optimal choices and delivery regiments of
inhibitors in preclinical models of prostate cancer, by evaluating their
general toxicity, adverse effects, and specificity in inducing apoptosis
and regression of prostate tumors. Possible directions to increase spec-
ificity by reducing systemic nonspecific effects may include the use of
prostate-selective PI3K inhibitor prodrugs and a new generation of
prostate-specific toxins in which antibody targeting is represented
by prostate-selective aptamers or other small molecule ligands [12,59].
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Figure W1. Purification and testing of J591PE. (A) Purification of
J591scFv and J591scFvPE38QQR (J591PE) was evaluated using
Coomassie staining after SDS-PAGE on 10% gels. Representative
pictures are reported. The most purified batches were also filtered
using a 0.22-μm syringe filter, evaluated for activity (see Figure 1D),
aliquoted, and stored in PBS at−20°C for subsequent experiments.
(B) J591PE selectively inhibits protein synthesis in PSMA-positive
C4-2Luc cells. PSMA-negative PC3, DU145, and PSMA-positive
C4-2Luc cells were treated with 100 μg/ml cycloheximide (CX) or
1 μg/ml J591PE for 5 hours and labeled with S35cystein-methionine
for 1 hour. C4-2Luc cells were also preincubated with 10 μg/ml J591
antibody for 1 hour before adding J591PE. Protein lysates (25 μg)
were separated by SDS-PAGE, transferred to nitrocellulose mem-
branes, and exposed to PhosphorImager screen for 5 days.
Figure W2. Analysis of long-term viability in prostate cancer cells
treated with ZSTK474, J591PE, or the combination. Combination
of 2 μg/ml ZSTK474with 1 μg/ml J591PE selectively and significantly
reduces viability in PSMA-positive C4-2 cells (A) at 48 hours, when
compared with controls or PSMA-negative PC3 (B) and DU145 (C)
cells (CX, 100 μg/ml cycloheximide; J591scFv was used at a con-
centration of 1 μg/ml). Cell viability was analyzed by MTT assay.
Figure W3. Inhibition of PI3K by ZSTK474. Titration of ZSTK474 in
C4-2 cells showed that maximal inhibition of PI3K is exerted at
2 μg/ml (5 μM), by monitoring the p-AKT levels at T308 and S473, at
6 hours. A representative Western blot panel showing also the phos-
phorylation status of BAD (S112), a downstream target of AKT (vehicle,
DMSO), is reported.
Figure W4. Induction of apoptosis in prostate cancer cells by combination of ZSTK474 and J591PE. (A) Combination of ZSTK474 and
J591PE promotes apoptosis at 6 hours in LNCaP and C4-2 cells, as suggested by the analysis of caspase 3 activity, cleavage of effector
caspases 3 and 7, cleavage of PARP, and analysis of cell morphology by time-lapse video recording. (B) Combination of ZSTK474 and
J591PE does not increase apoptosis in BT549 cells, when compared to single-agent treatments. Results are expressed as means ±
SEM, n = 2 (caspase 3 assay) and n = 4 (time-lapse video microscopy). Representative Western blots and time-lapse video microscopy
frames (original magnification, ×20) are shown (vehicle, DMSO; combination, ZSTK474 + J591PE).
Figure W4. (continued).
Figure W5. Combination of ZSTK474 and J591PE does not increase caspase 3 activity or PARP cleavage in PSMA-negative WF3, PC3,
BT549, and DU145 cells. (A) Caspase assays in DU145, WF3, PC3, and BT549 cells treated with ZSTK474, J591PE, or the combination
of ZSTK474 and J591PE. As a positive control for protein synthesis inhibition, cycloheximide (CX) was used, which significantly increased
caspase 3 activity when combined with ZSTK474. (B) Western blot analysis of full-length caspase 3 and cleaved PARP in WF3 cells treated
with ZSTK474 alone or in combination with J591PE. (C) Western blot analysis of DU145 cells treated with ZSTK474 alone or in combination
with J591PE. Cycloheximide (CX) was used as a positive control for protein synthesis inhibition. PI3K inhibition was followed by monitoring
p-AKT (T308 and S473) and p-BAD (S112) levels, downstream targets of PI3K. Insulin-like growth factor 1 (IGF-1; 500 ng/ml) treatment of DU145
cellswas usedasa positive control for PI3Kactivation. The arrowpointed at the cleavedcaspase7 fragment and its quantification. Treatments
were normalized to their respective controls (vehicle, DMSO; combination, ZSTK474 + J591PE; CX, cycloheximide). Results are expressed
as means ± SEM, n = 2. Representative Western blots are shown.
Figure W5. (continued).
Figure W6. (A) Dynamics of luminescence of C4-2Luc tumors after a single local injection of PBS, J591PE (2.5mg/kg), or J591scFv (2.5mg/kg).
Luminescence was monitored for 6 days by optical imaging and expressed as fold change compared to luminescence at day 0. Results are
expressed as means ± SEM, n = 3 (J591scFv), n = 4 (PBS), and n = 10 (J591PE). (B) Representative images of nude mice recorded on IVIS
100 luminescent imaging station showing ROI, 15 minutes after i.p. luciferin injection. (C) Representative images of nude mice reported in
Figure 6C and in B showing luminescence background inside ROI beside tumors treated with control vehicles (DMSO or PBS), ZSTK474,
J591PE, or J591scFv, 15 minutes after i.p. injection of luciferin.
Figure W6. (continued).
